You can buy or sell Acasti Pharma and other stocks, options, ETFs, and crypto commission-free!
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. Read More The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
52 Week High
52 Week Low
Simply Wall StMar 8
Introducing Acasti Pharma (CVE:ACST), The Stock That Tanked 90%
It is a pleasure to report that the Acasti Pharma Inc. (CVE:ACST) is up 56% in the last quarter. But that doesn’t change the fact that the returns over the last half decade have been stomach churning. Like a ship taking on water, the share price has sunk 90% in that time. So we don’t gain too much confidence from the recent recovery. The million dollar question is whether the company can justify a long term recovery. While a drop like that is definitely a body blow, money isn’t as important as health and h...
Stock Price, News, & Analysis for Acasti Pharma
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. MarketBeat Community Rating for Acasti Pharma (CVE ACST) Community Ranking: 2.7 out of 5 ( ) Outperform...
$0.32 per share